Startups
2021
ONIRIA THERAPEUTICS SLModulating cell dormancy to overcome cancer persistence - A shift in cancer treatment methodology
This unique method can be successfully used at all stages of the disease, from naïve primary tumors to recurrent resistant metastatic cancer – thus “making a world of difference“.
This unique method can be successfully used at all stages of the disease, from naïve primary tumors to recurrent resistant metastatic cancer – thus “making a world of difference“.
Address
Plaça d'Adolf Marsillach 6, 08035 Barcelona, Spain
Finance Data
CERCA ownership
Barcelona, Spain
2006
Vall d’Hebron Institut d’Oncologia (VHIO)
CERCA Center Contact
MD
Mario De la Cuesta Rivero
Vall d’Hebron Institut d’Oncologia (VHIO)Other Catalan Public owners
Logo
Logo
Status & Deeptech areas
Company Status & Company Deeptech AreasCurrent company status
DeepTech Area
Spinoff information
Company Description
At ONIRIA Therapeutics, we translate hard-won knowledge on cancer cell resistance to advanced treatments for patients. We have found that latent cells exist from the very beginning in primary tumors, later along undetectable residual disease phases and finally in recurrent tumors. These dormant cells are the long-term core of cancer persistence. But we have also discovered that tumor cell dormancy comes at a cost. While it enables the tumor to escape drug treatments, dormancy also exposes the cancer cells to unforeseen vulnerabilities. ONIRIA‘s novel strategy modulates the dormant state of cancer cells to exploit these vulnerabilities and overcome disease persistence, thereby prolonging patients‘ lives and ultimately cure them.
Product description
ONR-001 is a first-in-class molecule that allosterically activates TET2, a master epigenetic enzyme, causing tumor cells to enter a dormant state and even die.